Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Actelion
  6. Summary
    ATLN   CH0010532478

ACTELION

(ATLN)
 SummaryNewsCompany 
Company
More about the company
All news about ACTELION
2020ACTELION : Pharmaceuticals US, Inc, - Results from Expert Delphi Consensus Survey on Treat..
AQ
2017ACTELION : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exch..
GL
2017France's Sanofi raises earnings forecast, pleased with eczema drug uptake
RE
2017J&J sees sales growth in near-term; raises 2017 profit forecast
RE
2017J&J sees sales growth in near-term; raises 2017 profit forecast
RE
2017ACTELION : Befreiung von Publizitätspflichten zur Aufrechterhaltung der Kotierung
GL
2017ACTELION : Johnson & Johnson Completes Acquisition of Actelion
GL
2017ACTELION : Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on S..
PU
2017ACTELION : announces changes to its executive team upon completion of the transaction with..
GL
2017ACTELION : Spin off
FA
2017Johnson & Johnson expects to complete Actelion purchase on June 16
RE
2017Johnson & Johnson expects to complete Actelion purchase on June 16
RE
2017Johnson & Johnson expects to complete of Actelion offer on June 16
RE
2017ACTELION : Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on S..
GL
2017ACTELION : Johnson & Johnson announces expected settlement of Actelion tender offer on Jun..
GL
More news
News in other languages on ACTELION
2018Après Bioverativ, Sanofi s'empare de la biotech belge Ablynx pour 3,9 mrd EUR
2018Après Bioverativ, Sanofi rachète la biotech belge Ablynx pour 3,9 mrd EUR
2018Avec Bioverativ, Sanofi devient un leader mondial dans l'hémophilie
2017GNW-NEWS : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exch..
2017ACTELION : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exch..
More news
Analyst Recommendations on ACTELION
More recommendations
Managers and Directors
Nicholas Franco Chief Business Development Officer & EVP
Sector and Competitors
1st jan.Capi. (M$)
ACTELION27.10%0
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
REGENERON PHARMACEUTICALS31.23%66 409
WUXI APPTEC CO., LTD.26.31%65 758
VERTEX PHARMACEUTICALS-13.76%51 819